Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Jayson, Gordon C
AffiliationPrincess Margaret Cancer Centre, Toronto, ON, Canada
MetadataShow full item record
AbstractThe ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression. We report the final overall survival results of the trial.
CitationStandard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. 2015: Lancet Oncol
JournalThe Lancet. Oncology